News
DNA-Technology has been developing, producing and introducing to laboratories high-tech equipment and kits for PCR (polymerase chain reaction) analysis since 1993.
main new
News
-
IVF/ICSI Success Rates and the Infectious Factor: Is There a Connection?
This is perhaps one of the most widely discussed and debated questions in reproductive medicine. Seeking to move closer to an answer based on the results of their own research, physicians from leading Austrian clinics specializing in assisted reproductive technologies (ART), together with specialists from DNA-Technology, undertook a dedicated study. Follicular fluid samples from 24 women undergoing IVF/ICSI procedures were selected for analysis, and the microbial spectrum was assessed using the FEMOFLOR®16 and ANDROFLOR®. It was found that the absence of bacterial DNA correlates with a high probability of successful fertilization. The key role in predicting ART outcomes appears to belong to the overall microbial impact leading to disruption of the dynamic balance of the microbiota.
This study focuses on investigating the role of the microbial component of ovarian follicular fluid in the effectiveness of assisted reproductive technology (ART) programs. Microbiological analysis was performed using the commercial FEMOFLOR®16 and ANDROFLOR® real-time PCR assays on the DTprime 5M1 real-time PCR instrument, manufactured by DNA-Technology.The relevance of this research lies in the persistent limitations of ART success rates despite significant technological progress in embryology. In a substantial number of cases, the causes of failed fertilization remain unclear even when morphological, clinical, and laboratory parameters are normal. Studying the follicular microenvironment, including its microbial component, represents a promising direction in the search for new biomarkers of oocyte quality and factors influencing reproductive outcomes.
The authors examine the hypothesis that local microbial contamination of the follicle may affect the functional competence of the oocyte and its capacity for fertilization. Unlike previous studies, this research analyzed two follicles from each patient, making it possible to minimize inter-patient variability and identify local effects within a specific follicle.
The key finding was the identification of a strong correlation between the presence of bacterial DNA in the follicle (increased total bacterial load, TBL) and failure of in vitro fertilization. Conversely, the absence of bacterial DNA was associated with a high likelihood of successful fertilization (classification accuracy approximately 85%). No specific microorganisms were identified as directly influencing the outcome. Most likely, the decisive factor is the total microbial load or a dysbiotic state.
The study also demonstrates pronounced microbiome heterogeneity even between follicles of the same patient, indicating the local (microecological) nature of microbial influence. Proposed mechanisms include inflammatory changes, impaired granulosa cell function, and disruption of the hormonal regulation of oocyte maturation.
This work supports the concept that the follicular fluid microbiome is involved in the regulation of fertility and raises the possibility of its future use as a biomarker of ART effectiveness. At the same time, it underscores the need for further studies to identify specific molecular mechanisms.
Read the full publication via link.
-
Microbiome Throughout Life. Conference results
From March 19 to 21, 2026, the international conference Microbiome Throughout Life – Translating New Science into Clinical Practice was held in Belgrade, Serbia, bringing together over 200 participants and 55 international speakers from the fields of gastroenterology, obstetrics and gynecology, microbiology, immunology, neonatology, endocrinology, and biotechnology. DNA-Technology participated as a Platinum Sponsor and showcased its molecular diagnostic solutions for microbiome analysis.
As part of the scientific program, Professor Ekaterina Voroshilina delivered two presentations that generated strong interest from the professional audience.
Within the scientific session, she presented “Gut Microbiota in Children with Neurodevelopmental Disorders”, and in the industry session, DNA-Technology presented “How Molecular Testing Can Improve Vaginal Microbiome Evaluation in Women’s Health”.
Recordings of both lectures are available via links:
“Gut Microbiota in Children with Neurodevelopmental Disorders”.
“How Molecular Testing Can Improve Vaginal Microbiome Evaluation in Women’s Health”.The conference clearly demonstrated the growing interest of the professional community in the clinical application of microbiome research. At the company’s booth, particular attention was given to the ENTEROFLOR® Kiddy test and the new FEMOFLOR® II product line, which became key topics of discussion with clinicians, researchers, and industry partners. The focus was placed on clinical utility, diagnostic value, and the potential for broader implementation of these solutions in routine laboratory and clinical practice.
The main practical outcome of participation was the establishment of direct connections with the scientific community and healthcare professionals, enabling further discussions on collaborative research, advancement of microbiome studies, and integration of modern diagnostic solutions into clinical workflows.
An additional advantage was the presence of DNA-Technology’s partners at the conference. RIDACOM and BIOTEK Solutions participated as General Sponsors, while our partner Prediag was also present at the event. This allowed interested participants not only to explore DNA-Technology’s solutions, but also to immediately engage with regional partners, exchange contacts, and discuss concrete next steps for cooperation.
The contribution of partners to the scientific program was also notable. Colleagues from Macedonia presented a poster on vaginal microbiota dysbiosis using the Femoflor®16 test, while colleagues from Bulgaria showcased research on the isolation of lactobacilli and bifidobacteria from breast milk and infant stool using the ENTEROFLOR® Kiddy kit. These studies further highlighted the scientific relevance and practical value of the company’s solutions in the international professional community.
Our participation in the conference became a full-scale working session for knowledge exchange, strengthening professional relationships, and advancing the microbiome diagnostics field with the goal of developing new diagnostic solutions and expanding their clinical application.
-
DNA TECHNOLOGY AT WHX LABS KUALA LUMPUR 2025
From July 16 to 18, we participated in WHX Labs, the leading medical laboratory technology exhibition in Southeast Asia.
The event brought together over 350 exhibitors and 10,000 professionals, serving as a key platform for knowledge exchange, innovation presentations, and partnership agreements in the field of laboratory diagnostics.
At our booth, we showcased the company’s latest developments:
- DTstream Robotic Stations – Automation for PCR laboratories with ultra-precise dosing.
- DTprime II Detection Amplifiers – Enhanced sensitivity and faster analysis.
- PCR and NGS reagent kits.We placed special emphasis on reproductive health solutions. Our technologies play a key role in IVF, ensuring:
- Accurate diagnosis of latent infections (BacScreen OM + BacResist GLA).
- Microbiome screening before pregnancy (Femoflor®/Androflor®).Reduced risk of complications:
- AneuScreen – Non-invasive prenatal DNA test (NIPT) for detecting fetal aneuploidies from maternal blood.
- AneuPGT – Preimplantation genetic testing (PGT) for identifying chromosomal abnormalities in IVF embryos.On July 17, as part of the "Molecular Diagnostics and Genetics" conference supported by our company, a presentation by Dr. Med. Sci., Prof. Ekaterina Voroshilina titled "New Approaches to Overcoming Reproductive Challenges in Couples" was delivered. The talk sparked active engagement among reproductive medicine and genetics specialists.
Participation in WHX Labs Kuala Lumpur 2025 allowed us to:
- Strengthen our position in the Asian market.
- Establish new business connections.
- Demonstrate cutting-edge laboratory diagnostics solutions.We thank our visitors and partners for their interest.
We are in Telegram»
-
DNA-TECHNOLOGY PRESENTED COMPANY SOLUTIONS DURING THE BUSINESS MISSION IN MEXICO
DNA-Technology took part in the business mission of Russian companies to Mexico (August 19 to 21, 2025), organized by the Moscow Export Center (MEC). The mission was aligned with ExpoMed in Mexico City, one of the largest international medical technology exhibitions in Latin America.
As part of the delegation, Russian companies negotiated and business meetings with both government and private medical organizations in Mexico, and also participated in industry-specific panel discussions.
Representing DNA-Technology, Head of the International Sales Department Sergey Labutin:
- presented the company’s products and molecular diagnostics technologies at the ExpoMed venue;
- delivered presentations on innovative solutions in laboratory diagnostics;
- conducted negotiations on potential cooperation with representatives of Mexican governmental and private institutions at key venues
the Embassy of the Russian Federation, CONCAMIN / CONOSINTRA, and the Cámara Nacional de Comercio de la Ciudad de México (National Chamber of Commerce of Mexico City);
- gave interviews to local media, emphasizing the importance of Russian-Mexican cooperation in medicine and biotechnology.
Mexican colleagues highly appreciated the company’s products and technological solutions, showing particular interest in:
- automated diagnostic solutions in both human and veterinary medicine;
- innovative equipment systems and PCR-based diagnostic kits.
It was especially noted that Russian solutions are distinguished by their high quality and price accessibility, making them highly competitive in the Latin American market.
DNA-Technology considers the Latin American market as a strategically important direction for the export of high-tech products. Participation in the business mission marked a significant step in expanding the company’s international presence and laid the foundation for future joint projects with Mexican partners.
At the same time, much work still lies ahead to develop and strengthen these business relations. Nevertheless, we are confident that this cooperation has significant potential and opens up broad prospects for both sides.
-
OUTCOMES OF WHX CAPE TOWN 2025: DNA-TECHNOLOGY STRENGTHENS ITS PRESENCE IN THE AFRICAN LABORATORY DIAGNOSTICS MARKET
From September 2nd to 4th, 2025, the WHX Cape Town 2025, the largest African exhibition of medical and laboratory technologies, was successfully held in Cape Town, South Africa. DNA-Technology acted as the gold sponsor of this key industry event, and our booth enjoyed incredible popularity throughout all the exhibition days, attracting a many of visitors.
The event proved to be an exceptionally productive platform, allowing us not only to present our innovations but also to establish new business connections and partnerships with key market players.
Among the numerous visitors, our key developments drew particular attention:
- DTstream Robotic Stations — a revolutionary solution for laboratory process automation that generated keen interest among attendees.
- The latest DTprime II Amplifiers — next-generation equipment that impressed specialists with its unique detection accuracy.
- FEMOFLOR ®/ANDROFLOR® diagnostic systems — the recognized gold standard in urogenital microbiome research.The guests paid especially close attention to the presentation on the women's health solution. Specialists showed high interest in the capabilities of:
BacScreen OM for detecting opportunistic microflora.
The new FEMOFLOR®II for a comprehensive assessment of the microbiocenosis state.
These solutions were also reflected in the scientific report "Assessing urinary microbiota in chronic cystitis by PCR method," presented by our experts at the Labs Conference. The report provided a detailed analysis of a new, more accurate approach to diagnosing chronic cystitis using comprehensive PCR analysis, which allows for assessing the state of the entire urinary microbiota rather than searching for a single pathogen. The presentation of clinical cases and new laboratory diagnostics capabilities sparked an active discussion among specialists.
We thank everyone who visited our booth.
The success at WHX Cape Town 2025 and the interest in our products inspire us to further develop and strengthen partnerships in the dynamically growing African market.Check out the video to see how the event went.
- Previous page
- 1
- 2
- Next page